Matthew Plavan
2013 - Cesca Therapeutics
In 2013, Matthew Plavan earned a total compensation of $403K as Chief Executive Officer thru at Cesca Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Option Awards | $88,000 |
|---|---|
| Salary | $315,000 |
| Total | $403,000 |
Plavan received $315K in salary, accounting for 78% of the total pay in 2013.
Plavan also received $88K in option awards.
Rankings
In 2013, Matthew Plavan's compensation ranked 10,025th out of 12,286 executives tracked by ExecPay. In other words, Plavan earned more than 18.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,025 out of 12,286 | 18th |
Division Manufacturing | 3,727 out of 4,612 | 19th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 521 out of 681 | 24th |
Industry group Laboratory Apparatus And Analytical, Optical, Measuring, and Controlling Instruments | 146 out of 198 | 26th |
Industry Laboratory Apparatus and Furniture | 3 out of 14 | 79th |
Source: SEC filing on May 11, 2015.
Plavan's colleagues
We found five more compensation records of executives who worked with Matthew Plavan at Cesca Therapeutics in 2013.
2013
Hal Baker
Cesca Therapeutics
Former V.P., Commercial Operations & Marketing
2013
Ken Pappa
Cesca Therapeutics
V.P., Manufacturing and IT
2013
Kevin Cooksy
Cesca Therapeutics
V.P., Corporate Development & Scientific Affairs
2013
October Bessey
Cesca Therapeutics
Chief Financial Officer
2013
Dan Bessey
Cesca Therapeutics
Chief Financial Officer
News
Arcadia Biosciences CEO Matthew Plavan's 2021 pay jumps 102% to $1.6M
April 19, 2022
Arcadia Biosciences CEO Matthew Plavan's 2020 pay jumps 37% to $794K
April 20, 2021
Arcadia Biosciences CEO Matthew Plavan's 2019 pay stays at $581K
April 17, 2020
Arcadia Biosciences CEO Rajendra Ketkar's 2018 pay jumps 40% to $904K
April 18, 2019